TSE:OGI Organigram (OGI) Stock Price, News & Analysis C$1.32 +0.04 (+3.13%) As of 07/24/2026 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesBuy This Stock About Organigram Stock (TSE:OGI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Organigram alerts:Sign Up Key Stats Today's RangeC$1.28▼C$1.3250-Day RangeC$1.23▼C$1.6052-Week RangeC$1.20▼C$3.09Volume76,683 shsAverage Volume212,644 shsMarket CapitalizationC$185.82 millionP/E RatioN/ADividend YieldN/APrice TargetC$3.13Consensus RatingBuy Company Overview Organigram Inc. is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships. Read More Organigram Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreOGI MarketRank™: Organigram scored higher than 68% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingOrganigram has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and no sell ratings.Upside PotentialOrganigram has a consensus price target of C$3.13, representing about 136.7% upside from its current price of C$1.32.Amount of Analyst CoverageOrganigram has received no research coverage in the past 90 days.Read more about Organigram's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Organigram is -6.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Organigram is -6.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioOrganigram has a PEG Ratio of 0.42. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioOrganigram has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for OGI. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOrganigram does not currently pay a dividend.Dividend GrowthOrganigram does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest4 people have searched for OGI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership3.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net C$22,000.00 in company stock, which represents 0.0118% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Organigram insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$22,000.00 in company stock and sold C$0.00 in company stock.Percentage Held by Insiders31.32% of the stock of Organigram is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions3.89% of the stock of Organigram is held by institutions.Read more about Organigram's insider trading history. Receive OGI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Organigram and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OGI Stock News HeadlinesOrganigram Global Inc OGIJuly 7, 2026 | morningstar.comMAnalysts Offer Insights on Healthcare Companies: Organigram Global (OGI) and NeuroOne Medical Technologies (NMTC)May 14, 2026 | theglobeandmail.comALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's latest AI patent as the catalyst behind their next major call. They say a market pattern with a 100% historical track record is converging with this new breakthrough by end of month. The last time conditions aligned like this, investors had the chance to turn $10,000 into as much as $350,000 in roughly 12 months. Brown and Chaikin have released the full details for investors who want to get ahead of it.July 26 at 1:00 AM | Brownstone Research (Ad)Cannabis Revenue Decline Pressures Organigram Earnings Despite Germany Expansion (OGI)May 12, 2026 | finance.yahoo.comOrganigram Global Inc.April 13, 2026 | barrons.comISS Recommends Shareholder Support for Organigram Global Inc. (OGI)’s Acquisition of Sanity Group GmbHApril 2, 2026 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Organigram Global (OGI) and Spyre Therapeutics (SYRE)February 21, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: OrganiGram Holdings (OGI), Taysha Gene Therapies (TSHA) and BioRestorative Therapies (BRTX)February 20, 2026 | theglobeandmail.comSee More Headlines OGI Stock Analysis - Frequently Asked Questions How have OGI shares performed this year? Organigram's stock was trading at C$2.31 at the start of the year. Since then, OGI shares have decreased by 42.9% and is now trading at C$1.32. How do I buy shares of Organigram? Shares of OGI stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Organigram own? Based on aggregate information from My MarketBeat watchlists, some other companies that Organigram investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Innovative Industrial Properties (IIPR), Aurora Cannabis (ACB), Canopy Growth (WEED), Aphria (APHA) and NVIDIA (NVDA). Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryCannabis Current SymbolTSE:OGI CIKN/A Webwww.organigram.ca Phone844-644-4726FaxN/AEmployees987Year FoundedN/APrice Target and Rating Average Price Target for OrganigramC$3.13 High Price TargetC$3.25 Low Price TargetC$3.00 Potential Upside/Downside+136.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)C($0.21) Trailing P/E RatioN/A Forward P/E Ratio8.09 P/E Growth0.42Net Income-C$57.23 million Net Margins-9.19% Pretax MarginN/A Return on Equity-6.83% Return on Assets-5.56% Debt Debt-to-Equity Ratio2.20 Current Ratio2.82 Quick Ratio2.62 Sales & Book Value Annual SalesC$274.19 million Price / Sales0.68 Cash FlowC$0.34 per share Price / Cash Flow3.85 Book ValueC$2.83 per share Price / Book0.47Miscellaneous Outstanding Shares140,775,000Free FloatN/AMarket CapC$185.82 million OptionableNot Optionable Beta1.45 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (TSE:OGI) was last updated on 7/26/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredUniversal basic income is not impossible. It exist (kind of)Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...Freedom Financial | SponsoredThree oil giants buried the same discovery for 50 yearsIn 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...Behind the Markets | SponsoredBlackRock's $2.8B Clue (most investors missed)BlackRock's new fund on the emerging financial grid hit 2.8 billion in assets in just three months, according ...Awesomely | SponsoredThe invention Elon called the greatest in historyJeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI pa...Brownstone Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organigram Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organigram With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.